prodrug

October 19, 2018October 19, 2018

NV354, Potential Therapy for Mitochondrial Diseases, Shows Promise in Preclinical Studies

News

NeuroVive Pharmaceutical’s therapeutic candidate NV354 for mitochondrial diseases, such as Leigh syndrome, was able to restore the body’s own energy substrate — succinate — in an in vivo model of ... Read more

September 7, 2018September 7, 2018

$4M Grant Will Help Advance Research into NVP015 Treatment for Genetic Mitochondrial Disease

News

The U.S. Department of Defense (DoD) has awarded a $4 million, three-year grant to the Children’s Hospital of Philadelphia (CHOP) to advance NeuroVive Pharmaceutical AB‘s NVP015 program for genetic ... Read more

Pin It on Pinterest